Focus Middle East and India

Chief Scientific Officer Dr. Baumann on FOCUS’ offering for Indian pharmaceutical companies

admin — Fri, 05 Dec 2008 15:24:59 +0000

In a recent road-show FOCUS’ Managing Director and Chief Scientific Officer Dr. Matthias Baumann reported on the specific development challenges and business opportunities for Indian pharmaceuticals in European markets. He presented this information at various pharmaceutical and biotechnological operations in India.

We are pleased to offer a complimentary copy of this presentation for your personal use.

Please feel free to order your free copy of the presenation by filling out and submitting the request form below.

The FOCUS Middle East & India Team is looking forward to provide this information to you.

cforms contact form by delicious:days

FOCUS bridging services for established and emerging markets

admin — Sun, 09 Nov 2008 17:28:57 +0000

Globalisation and presence in emerging markets worldwide is key to future growth of the bio-pharmaceutical industry.

FOCUS offers bridging expertise with 25 bridging studies completed in the past 5 years.

Find further detailed information by clicking on the following link: brochure on FOCUS bridging studies

Free documentation: Success factors to achieve EU pharma product registration

admin — Tue, 07 Oct 2008 08:21:05 +0000

Western markets offer significant business opportunities for Indian pharmaceuticals. Thus, Indian pharma companies look for smart approaches towards product registration in western markets, such as in the EU or in the US, via EMEA or FDA, respectively.

FOCUS Clinical Drug Development GmbH (FOCUS-CDD) has many years of successful experience with EMEA and FDA submissions and registrations. Through it’s Dubai-based subsidiary "FOCUS Middle East & India" this competence is offered to the Indian pharmaceutical industry. A particular strength of FOCUS-MEI is it’s international staff that comprises German and Indian drug development experts who are familiar wih both industry cultures.

The experts at FOCUS-MEI have compiled the documenation "Major success factors to achieve EU pharmaceutical product registration for Indian pharmaceutical products".

You can order your complimentary copy by contacting Dr. Chandrashekhar via chandrashekhar@avicennapharma.com.

Development of Indian Pharmaceuticals for Western Markets

admin — Tue, 23 Sep 2008 10:17:14 +0000

The Indian pharmaceutical industry has made great progress and moved up the value chain from generics to discovery based R&D. FOCUS wants to serve the Indian pharmaceutical industry and be their partner in the unique opportunity of developing new compounds, bridging India to Europe and major Western markets.

FOCUS Clinical Drug Development GmbH (www.focus-cdd.de) is an independent full service drug development house. The unique combination of drug development and clinical pharmacology know-how, together with an in-house infrastructure to support every aspect of the program including the conduct of the clinical studies ensures fast results in best quality and European standard.

We provide product consultancy, development planning with regulatory strategy for new chemical/biological entities, herbal products, generics plus and drug combinations (FDC).

FOCUS HQ is located in Neuss/Duesseldorf, Germany with affiliates in Heidelberg, Belgrade, Moscow, Jakarta and Dubai. Since inception by MBO from SmithKline Beecham more than 15 years ago it has successfully grown to become an established provider of comprehensive NCE/NBE development services to global pharmaceutical and biotech companies.

We FOCUS on:

Regulatory path finding and development planning
Integrated project management for a comprehensive and
internationally accepted data package
Clinical proof of concept studies
Full service up to registration for fixed dose combinations and value added Generics
Valuation of R&D portfolio and strategic advice
In-licensing service: providing early stage molecules to fill gaps in R&D portfolio
Out-licensing service: commercialization of in-house molecules to global Big Pharma